For one thing, a post-hoc analysis of the EVEREST trial for HF with reduced ejection fraction found that reduced serum albumin (ALB) and elevated total bilirubin (TB) were associated with adverse outcomes, while aspartate transaminase (AST) and alanine transaminase (ALT) were not [13]. The gene discussed is ALB; the disease is hydrops fetalis.